Quest Diagnostics (DGX) has been the centerpiece of numerous market updates. The company has made substantial strides in the development of diagnostic techniques especially for Alzheimer's disease with a breakthrough blood test named AD-Detect™ which offers impressive predictive accuracy. This innovation signifies substantial progress in Alzheimer's diagnosis. In other noteworthy news, Quest Diagnostics has also introduced an HPV specimen self-collection test for cervical cancer screening. They also have been advancing their growth strategy significantly, with a focus on five key areas projected to fuel double-digit expansion. Further, their earnings report has spotlighted substantial financial growth, with shares crossing the 2% yield mark and the dividend being increased to $0.80 per share. They have also sealed several key acquisitions and collaborations recently, including Google Cloud for enhanced data management and AI utilization. Its strategic approach and consistent performance have led to Quest Diagnostics being named to Fortune's World's Most Admired Companies list for the 11th consecutive year.
Quest Diagnostics DGX News Analytics from Tue, 11 Jun 2024 07:00:00 GMT to Fri, 11 Apr 2025 10:45:00 GMT -
Rating 8
- Innovation 9
- Information 9
- Rumor 4
